Journal issues > Issue 4, August 2018 > Highlights in multiple myeloma

Highlights in multiple myeloma

SUMMARY

In recent years, the treatment landscape of patients with relapsed refractory multiple myeloma (RRMM) changed dramatically following a long list of positive phase III studies evaluating novel treatment combinations. During EHA 2018 several new positive studies were added to this list, further broadening the treatment armamentarium for RRMM. Following the successes in the RR setting, several of these novel agents are now also being explored in newly diagnosed MM (NDMM) patients. At EHA 2018, updated results were presented with the daratumumab-VMP combination in older NDMM patients. In addition, the role of VRD consolidation in NDMM was assessed and overall survival (OS) data of the GIMEMA-MMY-3006 study were presented. The key messages of these and other studies will be discussed in this summary.

(BELG J HEMATOL 2018;9(4):141–5)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top